Physician profile
Khader Mustafa
NPI 1881078533
$4,063.56
in general payments reported to CMS, 2019-2025
21 companies · $961 in 2025
The $961 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,084 · 2020: $249 · 2021: $99.06 · 2022: $293 · 2023: $392 · 2024: $985 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.65 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,313.28 | 2019-2025 | |
| Amgen INC. | $841.30 | 2019-2025 | Tavneos, Enbrel, Krystexxa |
| Janssen Biotech, INC. | $281.81 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $243.60 | 2019-2025 | |
| Ucb, INC. | $213.85 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $209.61 | 2019-2024 | Orencia |
| Lilly USA, LLC | $142.29 | 2019-2025 | Taltz, Zepbound |
| Pfizer INC. | $138.13 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $137.00 | 2022-2025 | Saphnelo |
| Celgene Corporation | $81.61 | 2019 | |
| Glaxosmithkline, LLC. | $74.40 | 2019-2025 | Benlysta |
| Regeneron Healthcare Solutions, INC. | $72.03 | 2019 | |
| Horizon Therapeutics Plc | $60.28 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $59.15 | 2021-2023 | Acthar |
| Sobi, INC | $46.86 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $37.33 | 2022-2024 | Lupkynis |
| Radius Health, INC. | $31.15 | 2019 | |
| Hikma Pharmaceuticals USA | $31.01 | 2019 | |
| Fresenius Kabi USA, LLC | $19.38 | 2023 | Idacio |
| Electromed, INC. | $18.60 | 2019 | |
| Genentech USA, INC. | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khader Mustafa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.